Please use this identifier to cite or link to this item:
https://hdl.handle.net/10216/136238Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.creator | Felix, J | |
| dc.creator | Weinhäupl, K | |
| dc.creator | Chipot, C | |
| dc.creator | Dehez, F | |
| dc.creator | Hessel, A | |
| dc.creator | Gauto, DF | |
| dc.creator | Morlot, C | |
| dc.creator | Abian, O | |
| dc.creator | Gutsche, I | |
| dc.creator | Velazquez-Campoy, A | |
| dc.creator | Schanda, P | |
| dc.creator | Fraga, H | |
| dc.date.accessioned | 2021-09-20T10:52:15Z | - |
| dc.date.available | 2021-09-20T10:52:15Z | - |
| dc.date.issued | 2019 | |
| dc.identifier.issn | 2375-2548 | |
| dc.identifier.uri | https://hdl.handle.net/10216/136238 | - |
| dc.description.abstract | Coordinated conformational transitions in oligomeric enzymatic complexes modulate function in response to substrates and play a crucial role in enzyme inhibition and activation. Caseinolytic protease (ClpP) is a tetradecameric complex, which has emerged as a drug target against multiple pathogenic bacteria. Activation of different ClpPs by inhibitors has been independently reported from drug development efforts, but no rationale for inhibitor-induced activation has been hitherto proposed. Using an integrated approach that includes x-ray crystallography, solid- and solution-state nuclear magnetic resonance, molecular dynamics simulations, and isothermal titration calorimetry, we show that the proteasome inhibitor bortezomib binds to the ClpP active-site serine, mimicking a peptide substrate, and induces a concerted allosteric activation of the complex. The bortezomib-activated conformation also exhibits a higher affinity for its cognate unfoldase ClpX. We propose a universal allosteric mechanism, where substrate binding to a single subunit locks ClpP into an active conformation optimized for chaperone association and protein processive degradation. | |
| dc.description.sponsorship | This work was supported by Spanish Ministerio de Economia y Competitividad (BFU2016-78232-P) and Instituto de Salud Carlos III co-funded by European Union (PI15/00663 and PI18/00349, ERDF/ESF, “Investing in your future”). This work was financially supported by the European Research Council (ERC-Stg-2012-311318 to P.S.). J.F. is supported by an EMBO long-term post-doctoral fellowship (ALTF441-2017). Author contributions: J.F. prepared ClpP + inhibitor crystals, processed x-ray diffraction data, refined and analyzed crystal structures, performed MALLS and DLS experiments, prepared figures, and wrote the manuscript. K.W. performed solution NMR experiments, discussed results, and prepared figures. C.C. and F.D. designed, performed, and analyzed the MD simulations and prepared figures. A.H. performed site-directed mutagenesis and protein sample preparation. D.F.G. performed modeling and computational simulations proof of concepts and prepared figures. C.M. prepared ClpP crystals and collected x-ray diffraction data. O.A. performed and analyzed ITC experiments. I.G. designed research and discussed results. A.V.-C. performed and analyzed ITC experiments, prepared figures, discussed results, and wrote the manuscript. P.S. performed and analyzed NMR experiments, designed research, managed and prepared figures, discussed results, and wrote the manuscript. H.F. performed biochemical experiments and sample preparation for NMR and x-ray, managed and prepared figures, discussed results, and wrote the manuscript. Competing interests: The authors declare that they have no competing interests. Data and materials availability: All data needed to evaluate the conclusions in the paper are present in the paper and/or the Supplementary Materials. Additional data related to this paper may be requested from the authors. Coordinates and structure factors for TtClpP in complex with peptide or bortezomib have been deposited in the PDB with accession codes 6HWM and 6HWN, respectively. | |
| dc.language.iso | eng | |
| dc.publisher | American Association for the Advancement of Science | |
| dc.relation.ispartof | Science Advances, vol.5(9):eaaw3818 | |
| dc.rights | openAccess | |
| dc.rights.uri | https://creativecommons.org/licenses/by-nc/4.0/ | |
| dc.subject.mesh | Allosteric Regulation | |
| dc.subject.mesh | Bacterial Proteins / antagonists & inhibitors | |
| dc.subject.mesh | Bacterial Proteins / chemistry | |
| dc.subject.mesh | Catalytic Domain | |
| dc.subject.mesh | Crystallography, X-Ray | |
| dc.subject.mesh | Endopeptidase Clp / antagonists & inhibitors | |
| dc.subject.mesh | Endopeptidase Clp / chemistry | |
| dc.subject.mesh | Protease Inhibitors / chemistry | |
| dc.subject.mesh | Thermus thermophilus / enzymology | |
| dc.title | Mechanism of the allosteric activation of the ClpP protease machinery by substrates and active-site inhibitors | |
| dc.type | Artigo em Revista Científica Internacional | |
| dc.contributor.uporto | Instituto de Investigação e Inovação em Saúde | |
| dc.identifier.doi | 10.1126/sciadv.aaw3818 | |
| dc.relation.publisherversion | https://advances.sciencemag.org/content/5/9/eaaw3818 | |
| Appears in Collections: | I3S - Artigo em Revista Científica Internacional | |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| 10.1126-sciadv.aaw3818.pdf | 6.26 MB | Adobe PDF | ![]() View/Open |
This item is licensed under a Creative Commons License
